Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422446 · ClinicalTrials.gov registry record · Phase 3
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT02422446 is a Phase 3 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 2 participants.
The verdict
NCT02422446, a Phase 3 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot trial seeks to obtain preliminary data on the effects of eicosapentaenoic acid (EPA) (4g/d) on endothelial function measured via endopat2000 after 12 weeks of intervention among adults with elevated triglycerides and type 2 diabetes.
Interventions
- DRUG Icosapent ethyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02422446
The ClinicalTrials.gov registry entry for NCT02422446 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Icosapent ethyl is the first listed.
NCT02422446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02422446 about?
NCT02422446 is a clinical study titled "Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects". This pilot trial seeks to obtain preliminary data on the effects of eicosapentaenoic acid (EPA) (4g/d) on endothelial function measured via endopat2000 after 12 weeks of intervention among adults with elevated triglycerides and type 2 diabetes.
What is the current status of trial NCT02422446?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2015-04. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT02422446?
The interventions under investigation include: Icosapent ethyl (DRUG).
Who is sponsoring clinical trial NCT02422446?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.